Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study
Abstract Background The 340B Drug Pricing Program has been controversial since its inception in 1992, a major criticism being that 340B hospitals use more outpatient drugs, and more expensive drugs, because of financial incentives to “make money” through the program. The goal of this study was to de...
Saved in:
Main Authors: | Jianhui Hu, David R. Nerenz |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12913-024-12188-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INTERRELATION OF CONCEPTUAL CATEGORIES “STOCKS”, “COSTS” AND “EXPENSES” AND SEQUENCE OF PRESENTING THEM IN THE FINANCIAL REPORTING
by: O. A. Ageeva
Published: (2020-05-01) -
Symptoms affecting patient’s intake of food with lymphoma in outpatient chemotherapy
by: Andressa Madalozo Laffitte, et al.
Published: (2015-07-01) -
On the MTD paradigm and optimal control for multi-drug cancer chemotherapy
by: Urszula Ledzewicz, et al.
Published: (2013-03-01) -
On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach
by: Urszula Ledzewicz, et al.
Published: (2017-01-01) -
Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia
by: Tong-Yoon Kim, et al.
Published: (2025-01-01)